Skip to main content

Table 2 Univariate and multivariate analysis for relapse, DFS, and OS

From: Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data

Variable Relapse DFS OS
Univariate Multivariate (HR) Univariate Multivariate (HR) Univariate Multivariate (HR)
Donortype HID vs MSD P= .034 P= .047 (0.615)
95%CI 0.381–0.994
P= .665 P= .832
Male/female P= .362 P= .680 P= .433
Patient age, ≥ 28 years old vs < 28 years old P= .183 P= .219 P= .376
AML/non-AML P= .204 P= .518 P= .448
Genetics:poor-risk vs others P= .321 P= .254 P= .489
Disease stage at transplants:relapse refractory vs PIF P= .048 P= .121 (1.449)
95%CI 0.907–2.314
P= .084 P= .148 (1.288)
95%CI 0.914–1.815
P= .131
WBC count at diagnosis:high vs others P= .659 P= .343 P= .247
BM blasts before conditioning, ≥ 32% vs < 32% (median) P= .191 P= .206 P= .245
BM blasts on day 0, ≥ 3% vs < 3% (median) P= .004 P= .037 (1.652)
95%CI 1.032-2.640
P< .001 P= .005 (1.630)
95%CI 1.162-2.288
P= .001 P= .011 (1.573)
95%CI 1.110-2.229
MRD status post-transplant, pos vs neg P= .002 P = .003 (2.019)
95%CI 1.267–3.216
P= .005 P= .003 (1.668)
95%CI 1.185–2.347
P= .019 P= .027 (1.490)
95%CI 1.048–2.121
DLI vs no DLI P= .025 P= .034 (0.561)
95%CI 0.329–0.957
P< .001 P< .001 (0.402)
95%CI 0.275–0.588
P< .001 P< .001 (0.423)
95%CI 0.289–0.620
II-IV aGVHD vs 0-I aGVHD P= .212 P= .530 P= .558
cGVHD vs no cGVHD P= .003 P= .023 (0.580)
95%CI 0.363–0.928
P= .003 P= .016 (0.659)
95%CI 0.470–0.925
P= .050 P= .108 (0.788)
95%CI 0.557–1.116
  1. HID haploidentical related donor, MSD matched sibling donor, AML acute myelogenous leukemia, non-AML acute leukemia other than AML, OS overall survival, DFS disease free survival, PIF primary induction failure, BM bone marrow, high WBC count at diagnosis WBC count ≥ 30,000 per mm3, MRD minimal residual disease